ContributorsPublishersAdvertisers

Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple Myeloma

onclive.com
 2022-01-17

Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma. Laura Finn, MD, associate program director, Hematology/Oncology Fellowship Program, associate program director, Bone Marrow Transplant, hematology research chair, Precision Cancer Therapies Program, Ochsner Health, discusses the utility of belantamab mafodotin-blmf (Blenrep) in late relapsed multiple...

www.onclive.com

Comments / 0

Comments / 0